The FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) (NCT01764633) [115,117] and the GLAGOV (Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound) (NCT01813422) studies [118] reinforced the important roles of PCSK9 inhibitors in CAVD treatment. Here, PCSK9 is linked to congenital bilateral aplasia of vas deferens from CFTR mutation.